Lionel Bosquée

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 520 citations · Full text

Oncology, Medicine, Metronomic Therapy +8

Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma

Kevin Hollevoet, Kristiaan Nackaerts, J. Thimpont et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 95 citations

Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy

Nicole Barthelemy-Brichant, Lionel Bosquée, Didier Cataldo et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 93 citations · Full text

Inflammation, Radiation Medicine, Inflammatory Lung Disease +11

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

Kevin Hollevoet, Kristiaan Nackaerts, Robert C. Gosselin et al. · Journal of Thoracic Oncology · 2011 · 82 citations · Full text

Sclerostin, Bone Morphogenic Protein, Megakaryocyte Potentiating Factor +8

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Jean-Louis Pujol, Johan Vansteenkiste, Tommaso Martino De Pas et al. · Journal of Thoracic Oncology · 2015 · 60 citations · Full text